Introduction
Since its widespread clinical introduction in the late 1980s, prostate-specific antigen (PSA) testing has gained popularity and has revolutionized the diagnosis of prostate cancer [1] . PSA is a kallicrein-like serine protease (33 kDa) produced almost exclusively by the epithelial cells of the prostate. Prostate cancer is commonly associated with serum PSA levels that are higher than those observed in benign prostatic hyperplasia (BPH), and thus has been widely used to screen the malignant condition from the benign one. In fact, PSA level as an independent variable is a better predictor of cancer
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As the PSA value lacks sensitivity and specificity for detection of prostate cancer, alternative PSA derivatives have been evaluated for potential use in testing: free/total PSA (f/t PSA) [6] and PSA velocity (PSAV). PSAV has been identified as a potential clinical marker for this purpose. A PSAV of 0.75 ng mL -1 per year, or an annual increase of 20%, is suggestive of prostate cancer [7] [8] [9] [10] [11] , and this level is accepted as a valid parameter for indicating prostate biopsy. Moreover, PSAV is associated with some characteristics of tumor aggressiveness, such as Gleason score [12] , and a PSA increase of > 2.0 ng mL -1 in the year before diagnosis has been found to be associated with a higher risk of death due to prostate cancer after radical prostatectomy or radiation therapy [13, 14] . A more recent study suggested that the cutoff for distinguishing the most aggressive forms of prostate cancer could be set at 0.35 ng mL -1 per year [15] .
However, it is necessary to distinguish the increases in PSA caused by the presence of cancer tissue from the physiological fluctuations of PSA. Several studies have investigated PSAV in the cancer population compared with PSAV in the non-cancer population; however, an adequate analysis of longitudinal fluctuation in the normal population has been lacking. In addition, the majority of studies investigating a PSAV threshold have been done in a selected population, usually composed of relatively young men, and have thus failed to detect the underlying physiological fluctuation that may occur in middle-aged or elderly men.
The aim of our study was to retrospectively assess PSA variations in elderly men who had PSA values < 2.0 ng mL -1 for a 5-to 10-year period in an attempt to define physiological fluctuation. The research focuses on PSA kinetics, and the results will contribute to defining the threshold of PSAV as a diagnostic tool for prostate cancer.
Materials and methods
Beginning in March 2006, we analyzed retrospective PSA data from the Central Laboratory of the Hospital-University of Modena (Modena, Italy), in search of a specific cohort of male patients aged > 75 years in 2005 and with PSA values < 2.0 ng mL -1 . For each subject, a retrospective search for PSA values recorded over the previous 10 years was made for the purpose of creating a database of patients meeting the following criteria: (1) a minimum of five PSA measurements, (2) over at least 5 years. The exclusion criteria were: (1) a PSA level < 0.2 ng mL -1 at every test and (2) having had more than one PSA test each year. These criteria were intended to reduce the risk of including subjects with clinical prostatis or of a diagnosis or recurrence of prostate cancer.
Annual PSA measurements were assessed longitudinally and collected in a database. The variation from the first to the last PSA measurement was calculated for each patient, as well as the variation from the lowest to the highest PSA value throughout the course of followup, to assess the major sources of individual variation. These two variables were divided by the number of years of follow-up to obtain the mean annual variation in PSA from the first to the last and from the lowest to the highest measurement for each patient.
All data were entered in a statistical database (Statistical Package for Social Sciences for Windows, version 13; SPSS, Chicago, IL, USA). Descriptive analyses of all variables were recorded, and statistical analyses were performed using the paired samples t-test and the Mann-Whitney U test. The cutoff for statistical significance (P) was fixed at 0.05.
Results
Throughout 2005, data from 20 000 patients aged > 75 years and with a PSA < 2.0 ng mL -1 were collected. In total, 1 327 subjects fit the inclusion criteria (more than five PSA measurements for at least 5 years) and were eligible for the study.
The in the first PSA measurement). Of the 1 327 subjects, we studied a subgroup of 71 individuals with 7 years of consecutive PSA assessment. The fluctuation across years of observation was not significant (P = 0.137 between the 1st and 2nd years, P = 0.162 between the 2nd and 3rd years, P = 0.166 between the 3rd and 4th years, P = 0.67 between the 4th and 5th years, P = 0.88 between the 5th and 6th years and P = 0.694 between the 6th and 7th years [ Figure 2] ). For these 71 individuals, we calculated the mean PSA values from the first to the last measurement, fluctuation from the lowest to the highest measurement and PSAV; the results of these calculations were 0.06 ± 0.52 ng mL -1 (range: -1.22 to 1.55 ng mL -1 ), 0.02 ± 0.80 ng mL -1 (range: -1.9 to 1.8 ng mL 
Discussion
PSA assessment has been widely performed because of its usefulness in the diagnosis of early prostate cancer, with the measurement of PSAV improving the detection of such neoplasm. In the previous study focusing on PSA kinetics, Carter et al. [7] found that PSA level as a function of time in patients with localized prostate cancer was significantly higher than that in men without prostate cancer 5 years before diagnosis. Several authors have concluded that the increase in PSA values in patients with prostate cancer is 10-fold greater than in the case of BPH (0.3 ng mL -1 ) [7, 15, 16] . However, there are physiological and biological fluctuations in PSA level that can occur even in noncancer conditions. For example, Tchetgen et al. [17] reported a statistically significant increase in PSA levels after ejaculation in 87% of men older than 50 years. Rapid increases in PSA values were described even after digital rectal examination or cystoscopy [1] , and, as published recently, sexually transmissible infections can induce a 40% increase in PSA [18] . Beyond the fluctuation owing to ejaculation, sexual function or medical problems, Roehrborn et al. [19] reported that in between the 2nd and 3rd years; P = 0.166 between the 3rd and 4th years; P = 0.67 between the 4th and 5th years; P = 0.88 between the 5th and 6th years; and P = 0.694 between the 6th and 7th years).
295 subjects with initial PSA levels < 10 ng mL
, 33% showed changes of more than ± 1.0 ng mL -1 in 90 days. Similarly, Riehmann et al. [20] reported a biological fluctuation of 55% in 39 subjects without prostate cancer in whom PSA was measured more than three times, with an average measurement interval of 10.3 months. It is necessary to optimize the calculation method, measurement interval and cutoff values to distinguish the PSAV rise due to prostate cancer from that due to physiological fluctuation.
For the most part, the reported studies consider PSAV with regard to the diagnosis of prostate cancer as follows: a rapid improvement before the cancer diagnosis can suggest the aggressiveness of the pathology, as stated by D'Amico and co-workers [13, 14] .
Considering the importance of PSAV and its clinical application in the field of prostate cancer, it is also necessary to measure PSA kinetics in a large healthy population. For this purpose, we entered the Central Laboratory of the Hospital-University of Modena, searching for a specific population aged > 75 years and with PSA value < 2.0 ng mL -1 . In those who meet these criteria, the risk of prostate cancer is very low; although a valid PSA threshold does not exist, Ito et al. [21] described an age-specific reference range of PSA that can increase the sensitivity, specificity and efficiency of PSA to 92.4%, 91.2% and 84.3%, respectively. According to their finding, the cutoff value for patients aged > 75 years was set at 4.0 ng mL -1 . Similarly, if the recommended threshold for prostate biopsies in young men is set at 2.0 ng mL -1 , the prostate cancer risk in our cohort of patients is very low.
A minimum of 0.2 ng mL -1 was chosen in our study to exclude patients undergoing therapies that could lower the PSA value. For each patient, a retrospective history of all PSA values for the last 10 years was recorded to create a database enrolling subjects with at least five PSA assessments for at least 5 years.
The main bias of our retrospective research, as occurs in many other studies on screening populations, is that the risk of prostate cancer is consistent at any PSA value or range: failure to reach a certain cutoff cannot assure us about the absence of the neoplasm. We tried to minimize this risk by selecting an elderly population with PSA set < 2.0 ng mL -1 , which is a value in accordance with most recent suggestions about age-related PSA values. Another bias is the lack of clinical information: we tried to reduce this inaccuracy by excluding patients with two or more PSA assessments per year, thus avoiding the risk of clinical prostatis, diagnosis or recurrence of prostate cancer.
Beyond these biases, we think that the volume of the cohort in this large-scale study must be highlighted, with a total of 1 327 PSA values followed retrospectively for a minimum of 5 years, and thus representing the main impact and power of the research. In addition, the recent publication of similar studies [22] shows that this is a very current and relevant theme in the diagnosis of prostate cancer.
Our outcomes strengthen the point of view of Scales et al. [23] , who analyzed the benefit of PSA testing in men older than 75 years and concluded that up to a third of those patients have an average life expectancy of < 10 years.
As suggested in the recent 'prostate, lung, colorectal and ovarian cancer screening trial' [24] , screening steps can be optimized. The authors of that study concluded that screening every 5 years for baseline PSA < 1 ng mL -1 and every 2 years for PSA 1-2 ng mL
could result in a 50% reduction in PSA tests and in < 1.5% of men missing earlier positive screens. Our outcomes confirm that yearly repeated PSA assessment in an elderly population, with a potential life expectancy of < 10 years and with normal PSA values at baseline, may have low significance in urological practice and screening programs. However, although repeated PSA assessments lose significance in older population, a recent study by Ulmert et al. [25] showed the importance of PSA before the age of 50 years, invoking this marker as a predictor of prostate cancer up to 25 years later. This outcome confirms the need for a risk-stratified screening approach for clinically significant diseases.
Even though the popularity of PSA is widely debated owing to its lack of sensitivity and specificity and the absence of an agreed-upon threshold, it still remains the most powerful marker in the management of prostate cancer diagnosis. PSAV has gained popularity for improving the usefulness of this indicator, and several studies have focused on the variation characterizing cancerous degeneration. Longitudinal assessment of PSA in an elderly and supposedly healthy population may help define its physiological kinetics. Our study represents a long-term retrospective PSA observation in a population aged > 75 years: PSA variation from the first to the last and from the highest to the lowest values seems to be insignificant. Even if followed up year by year, PSA fluctuations seem insignificant.
